NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DRNA shares have increased by 50.4% and is now trading at $25.39. View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) announced its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.28 by $0.59. The biopharmaceutical company earned $34.03 million during the quarter, compared to analyst estimates of $59.61 million. Dicerna Pharmaceuticals had a negative return on equity of 74.79% and a negative net margin of 213.04%. View Dicerna Pharmaceuticals' earnings history.

11 analysts have issued 12 month price targets for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $34.20 in the next twelve months. This suggests a possible upside of 34.7% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals.

Press coverage about DRNA stock has trended somewhat negative on Saturday, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals saw a decline in short interest in June. As of June 30th, there was short interest totaling 2,960,000 shares, a decline of 7.8% from the June 15th total of 3,210,000 shares. Based on an average trading volume of 639,600 shares, the days-to-cover ratio is currently 4.6 days. Approximately 4.6% of the company's shares are sold short. View Dicerna Pharmaceuticals' Current Options Chain.

Some companies that are related to Dicerna Pharmaceuticals include Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), PPD (SDGR), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Legend Biotech (LEGN), Emergent Biosolutions (EBS), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN) and Nektar Therapeutics (NKTR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DRNA stock can currently be purchased for approximately $25.39.

Dicerna Pharmaceuticals has a market capitalization of $1.88 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]